IN2014DN00254A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00254A
IN2014DN00254A IN254DEN2014A IN2014DN00254A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A IN 254DEN2014 A IN254DEN2014 A IN 254DEN2014A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A
Authority
IN
India
Prior art keywords
compositions
treatment
invention include
include methods
adipose deposits
Prior art date
Application number
Inventor
Katherine Cernok
Kenneth Martinez
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014DN00254A publication Critical patent/IN2014DN00254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Embodiments of the invention include methods and compositions for treatment of adipose deposits.
IN254DEN2014 2011-07-20 2012-07-19 IN2014DN00254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509700P 2011-07-20 2011-07-20
PCT/US2012/047405 WO2013013042A1 (en) 2011-07-20 2012-07-19 Botulinum toxins for use in a method for treatment of adipose deposits

Publications (1)

Publication Number Publication Date
IN2014DN00254A true IN2014DN00254A (en) 2015-06-05

Family

ID=46601917

Family Applications (1)

Application Number Title Priority Date Filing Date
IN254DEN2014 IN2014DN00254A (en) 2011-07-20 2012-07-19

Country Status (12)

Country Link
US (1) US20140127188A1 (en)
EP (1) EP2734224A1 (en)
JP (1) JP2014520892A (en)
KR (1) KR20140082956A (en)
CN (1) CN103702681A (en)
AU (1) AU2012283968B2 (en)
BR (1) BR112014001066A2 (en)
CA (1) CA2841955A1 (en)
IN (1) IN2014DN00254A (en)
MX (1) MX2014000612A (en)
RU (1) RU2014103543A (en)
WO (1) WO2013013042A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9655926B1 (en) 2013-08-23 2017-05-23 Amiya Prasad Treatment for hair thinning and hair loss
WO2016021985A1 (en) * 2014-08-07 2016-02-11 김상덕 Composition, containing mixture of botulinum toxin and air, for facial contour correction, and method for facial contour correction using same
TWI757260B (en) 2015-12-18 2022-03-11 中國大陸商南大光電半導體材料有限公司 Tris(disilanyl)amine
MX2019005833A (en) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Transdermal delivery of large agents.
WO2018213710A1 (en) * 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK1086702T3 (en) 1994-05-09 2005-05-23 William J Binder Presynaptic neurotoxins for the treatment of migraine headaches
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
CN1803189B (en) 1997-07-15 2010-05-26 科罗拉多大学董事会 Use of neurotoxin therapy for treatment of urologic and related disorders
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
PT1729821E (en) * 2004-03-03 2013-10-23 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
PT3295955T (en) * 2005-12-01 2021-07-12 Univ Massachusetts Lowell Botulinum nanoemulsions
EP2197409A1 (en) * 2007-08-31 2010-06-23 DSM IP Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
US20090297632A1 (en) * 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
KR101848095B1 (en) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 Dermal delivery
JP6006940B2 (en) * 2009-03-02 2016-10-12 ヘクセル，ドリス Medical beauty fat atrophy method

Also Published As

Publication number Publication date
RU2014103543A (en) 2015-08-27
AU2012283968A1 (en) 2014-02-06
JP2014520892A (en) 2014-08-25
WO2013013042A1 (en) 2013-01-24
CA2841955A1 (en) 2013-01-24
BR112014001066A2 (en) 2017-02-21
CN103702681A (en) 2014-04-02
MX2014000612A (en) 2014-02-27
KR20140082956A (en) 2014-07-03
AU2012283968B2 (en) 2016-04-14
EP2734224A1 (en) 2014-05-28
US20140127188A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
MX2013011479A (en) Anti-fgfr4 antibodies and methods of use.
IN2015DN00127A (en)
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
PH12015500525A1 (en) Formulations of enzalutamide
GB201103062D0 (en) Method
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX2014002053A (en) Anti-mcsp antibodies.
MX355728B (en) Kinase inhibitors.
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
MX2013007168A (en) Anti-pcsk9 antibodies and methods of use.
MX355543B (en) Peptidomimetic macrocycles.
EP2688594A4 (en) Methods and compositions for the treatment of cancer
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX340555B (en) Antibodies against il-18r1 and uses thereof.
IN2014CN03555A (en)
IN2014DN00254A (en)
MX336323B (en) Anti-polyubiquitin antibodies and methods of use.
IN2014CN04634A (en)
IN2014DN09450A (en)
IN2013MU00848A (en)
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
IN2014CN00312A (en)
MX2013014488A (en) Methods and compositions for treating brain cancer.
MX2015007608A (en) Methods and compositions for inhibiting cnksr1.